Filing Flows › Maxcyte (MXCT) › Q4 2024
Maxcyte (MXCT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Maxcyte (MXCT) reported revenue of $8.7M for the fourth quarter 2024 (Q4 2024), -45% from a year earlier and +6% from the quarter before. Operating margin was -148.4%, net loss $10.6M (121.9% of revenue).
Maxcyte, Q4 2024: revenue $8.7M (-44% year over year), operating margin -148.4%, net loss $10.6M, operating cash flow −$7.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.7M | +6% | -45% |
| Operating profit | −$12.9M | — | — |
| Net earnings | −$10.6M | — | — |
| Operating cash flow | −$7.8M | — | — |
What changed
Revenue was $8.7M in Q4 2024, down 45% year over year and up 6% from the previous quarter. Product sales was the largest line at 67% of revenue.
Gross margin was 73.8%, down 16.2 points from a year earlier. Operating costs exceeded revenue by $12.9M, an operating margin of -148.4%. Operating expenses fell 13% while revenue fell 45%. The quarter ended with a net loss of $10.6M, narrower than the previous quarter's $11.6M loss. Non-operating items added $2.3M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$7.8M. Non-cash charges added back $1.1M of depreciation and $3.1M of share-based compensation. Working capital and other items used $1.4M. Capital expenditures of $147K exceeded it, leaving free cash flow of −$8.0M.
Questions
What was Maxcyte's revenue in the fourth quarter 2024?
Maxcyte (MXCT) reported revenue of $8.7M for the fourth quarter 2024 (Q4 2024), -45% from a year earlier and +6% from the quarter before.
Was Maxcyte profitable in the fourth quarter 2024?
Operating loss was $12.9M (-148.4% of revenue) and net loss $10.6M.
Source: Maxcyte 10-K on SEC EDGAR.